Related Experiment Videos
Clinical proteomics and biomarker discovery
Donald J Johann1, Michael D McGuigan, Amit R Patel
1NCI-FDA Clinical Proteomics Program, Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA. johannd@mail.nih.gov
Annals of the New York Academy of Sciences
|July 15, 2004
Summary
Improving disease detection relies on advanced serum biomarkers. Mass spectrometry analysis of proteomic patterns offers enhanced sensitivity and specificity for early diagnosis and patient risk stratification.
Area of Science:
- Biochemistry
- Proteomics
- Medical Diagnostics
Background:
- Early disease detection significantly improves patient outcomes through timely intervention.
- Current disease marker monitoring relies on single proteins, which often lacks sufficient sensitivity and specificity.
- Serum biomarkers are crucial for disease diagnosis, but require enhanced performance for reliable early detection and recurrence monitoring.
Purpose of the Study:
- To highlight the potential of mass spectrometry-derived proteomic pattern-based diagnostics.
- To emphasize the need for improved sensitivity and specificity in serum biomarkers for early disease detection and risk stratification.
- To discuss the development of platform technologies and bioinformatic tools for advancing proteomic diagnostics.
Main Methods:
- Analysis of the low molecular weight proteome using mass spectrometry.
- Development of modular platform technologies for concurrent experimentation and refinement.
- Creation of new bioinformatic tools for data management, analysis, and visualization.
Main Results:
- Mass spectrometry-based proteomic patterns demonstrate improved capabilities in early disease detection.
- New biomarker classes show promise for enhanced patient risk stratification and outcome prediction.
- Modular platforms and advanced bioinformatic tools facilitate the translation of these diagnostics.
Conclusions:
- Mass spectrometry-derived proteomic patterns represent a promising advancement in early disease detection.
- Further development and validation of multiplexed biomarkers using clinically engineered mass spectrometry systems are essential.
- Integrated approaches involving platform technology, bioinformatic tools, and advanced MS systems are key to clinical adoption.